The B-cell response to antigen is critically regulated by co-receptors. CD21 (complement receptor 2) amplifies the response to antigen linked to its ligands, specific C3 fragments. In contrast, human Fc receptor-like 5 (FCRL5), a novel IgG receptor, was reported to inhibit B-cell receptor (BCR) signaling. Here, we show that CD21 and FCRL5 physically associate, suggesting that immune complexes containing both C3 fragment and IgG could simultaneously engage the pre-assembled receptors. We found that activating signaling molecules such as CD19, active PLCγ2 and BTK were rapidly recruited to FCRL5 upon engagement, suggesting a novel activating function for FCRL5. We confirmed that FCRL5 through its ITIMs (immunoreceptor tyrosine-based inhibitory motif) inhibited BCR signaling in the absence of CD21 stimulation. In contrast, triple engagement of FCRL5, CD21 and the BCR led to a superior calcium response compared to CD21 and BCR co-stimulation, in both cell lines and tonsil B cells. Furthermore, the novel activating function was independent of established FCRL5 signaling motifs. While human peripheral B cells express either FCRL5 or CD21, we identified a sizable subset of tonsil B cells which co-express the two receptors. We propose that FCRL5 has dual signaling capacity, while CD21 co-engagement serves as molecular switch, converting FCRL5 from a negative to a positive co-receptor. In tissues, B cells that co-express FCRL5 and CD21 could robustly respond to IgG immune complexes loaded with C3 fragments.
Introduction
CD21 (complement receptor 2) assembles with CD19 and CD81 into a membrane complex that functions as a positive regulator of B-cell receptor (BCR) signaling, critical for T-cell-dependent antigen responses (1) (2) (3) . CD21 serves as the ligand-binding component of the complex and has multiple ligands. CD21 ligands are the C3 fragments iC3b, C3dg and C3d; CD23 and IFNα; in addition, CD21 serves as Epstein-Barr virus receptor (4) (5) (6) . The interaction of CD21 and C3 fragments represents an important link between the adaptive and innate immune systems, which is critical when antigen concentration is low, such as during initial pathogen encounter (2) . CD21 co-stimulation has minimal effect on strong BCR stimulation, but robustly promotes suboptimal BCR stimulation (7) (8) (9) . Antigens with covalently deposited C3 fragments, which serve as molecular adjuvants, can cross-link the specific BCR and the CD21 complex, lowering by orders of magnitude the amount of antigen required for activation (10) (11) (12) . CD19 serves as the major signaling unit in the complex, recruiting among others the signaling molecules Vav, PI3K and BTK, resulting in an intracellular calcium influx, activation of mitogen-activated protein kinases and ultimately cell proliferation (13) . CD19 activates Lyn, resulting in CD22 phosphorylation and delayed down-modulation of BCR signaling (14) . CD19 also exists in membrane forms lacking CD21 and has CD21-independent functions (15) .
The Fc receptor-like (FCRL) family in humans consists of six membrane proteins, FCRL1-6, and two cytoplasmic proteins, FCRLA and FCRLB (16) . FCRL1-5 are preferentially expressed on B cells and were all shown able to modulate BCR signaling (17) (18) (19) . Progress in understanding the functional roles of FCRL proteins is hampered by insufficient knowledge of their ligands and the very different organization of the FCRL gene family in mice and humans. FCRL ligands are emerging. Among the membrane FCRL, FCRL6 was reported to bind HLA-DR, whereas FCRL4 and FCRL5 bind IgA and IgG, respectively (20) (21) (22) . Therefore, the presence of FCRL proteins on B cells is anticipated to expand the known co-stimulatory mechanisms that regulate the B-cell response to antigen.
FCRL5, the largest member of the family, contains nine immunoglobulin-like extracellular domains and a cytoplasmic tail with two canonical immunoreceptor tyrosine-based inhibitory motif (ITIM) and two non-canonical immunoreceptor tyrosine-based activation motif (ITAM) signaling motifs. Using a chimeric receptor consisting of the FCRL5 cytoplasmic tail and the FcγRIIB extracellular and transmembrane regions, FCRL5 was demonstrated to inhibit B-cell activation (23) . Specifically, when co-ligated with the BCR, FCRL5 inhibited calcium mobilization and tyrosine phosphorylation. This inhibitory effect was shown to be mediated by SHP-1 engaging two ITIMs in the FCRL5 cytoplasmic tail. We and others reported FCRL5 to bind intact IgG (21, 22) ; therefore, IgG immune complexes could link the BCR and FCRL5 on antigen-specific B cells. FCRL5 binds IgG not simply based on isotype and is sensitive to both IgG2 deamidation and disulfide isoform structure (24) . FCRL5 is expressed on plasma cells and circulating atypical memory B cells lacking CD21 (25) . FCRL5 expression is induced upon BCR stimulation and is up-regulated in a number of B-cell malignancies (26) (27) (28) ; however, the role of FCRL5 in disease progression in unknown.
The discovery of IgG as a ligand for FCRL5 led us to hypothesize that immune complexes containing both IgG and complement C3 fragments could simultaneously engage FCRL5 and CD21 on B cells, resulting in potentially physiologically relevant functional responses. Here, we demonstrate that FCRL5 constitutively associates with CD21, while CD19 is rapidly recruited following FCRL5 engagement. Importantly, FCRL5 promoted BCR signaling when co-engaged with CD21, potentially representing a novel mechanism to robustly activate B cells.
Methods

Cells
We generated Daudi B-cell lines stably expressing wild-type or mutated FCRL5 by transfecting 10 6 cells with 2 µg of wild-type or mutated FCRL5 expression plasmid using Amaxa nucleofector and kit L (Lonza, Allendale, NJ, USA). Transfected Daudi cells were maintained in RPMI supplemented with 10% fetal bovine serum (FBS) and 2 mg ml −1 geneticin for ~6 weeks, until all cells homogeneously expressed FCRL5, as verified by flow cytometry staining using FCRL5 monoclonal antibody (mAb) clone F99 (gift of Satoshi Nagata). The FCRL5-positive mantle cell lymphoma line Rec-1 was maintained in RPMI with 10% FBS. Lymphocytes were isolated from human tonsils of anonymous donors, obtained from the Mid-Atlantic Cooperative Human Tissue Network, by manual disruption and purification by Ficoll separation, using standard procedures.
Mutagenesis of FCRL5
The plasmid expressing wild-type FCRL5 was obtained from Satoshi Nagata. Tyrosine-to-phenylalanine mutations were introduced into amino acids located in two ITAM-like (Y899/ Y912) and two ITIMs (Y924/Y954) using site-directed mutagenesis. The following primers were used to mutagenize the indicated tyrosines (only sense primers are listed with mutated bases italicised; anti-sense primers were complementary):
Y899F, Ccaagagcccacctttcacaatgtaccag Y912F, GAGctgcaaccagtgtTcactaatgcaaatcc Y924F, GAggagaaaatgtggtttTctcagaagtacgGATC Y954F, ggttcccctatcatctTctctgaagttaaggTG The intended mutations were confirmed by DNA sequencing.
Cell stimulation, immunoprecipitation and western blotting
Cells were stimulated with 1 µg ml −1 biotin-labeled goat anti-IgM, Fab fragment (Jackson ImmunoResearch, West Grove, PA, USA) and 5 µg ml −1 biotin-labeled anti-FCRL5 mAb (clone F99), Fab fragment, for 30 min on ice, followed by 6 µg ml −1 streptavidin for 20 min to cross-link the biotinlabeled proteins. Biotin-labeled Fab fragments of the FCRL5 mAb were made using a kit from Pierce (Rockford, IL, USA), following the manufacturer's instructions. In some experiments, actin polymerization was blocked by pre-incubating cells with 1 mM cytochalasin D (Sigma-Aldrich, St Louis, MO, USA) for 30 min at 37°C. Immunoprecipitated samples run on the same gel were obtained from the same volume of cell lysate containing the same amount of protein. Cells with pre-bound Fab antibodies were transferred to 37°C for the indicated time, washed with cold phosphate-buffered saline (PBS) and lysed in lysis buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM sodium vanadate, 1 mM phenylmethanesulfonyl fluoride, 1 µg ml −1 aprotinin and either 1% triton X-100 or 1% digitonin. Cell lysates were pre-cleared with 2 µg ml −1 non-specific antibody and protein A/G-Sepharose. Cleared supernatants were immunoprecipitated with 2 µg ml −1 CD21 clone HB5, CD19 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or FCRL5 clone F99 antibody for 2 h at 4°C, followed by protein A/G-Sepharose for 2 h at 4°C. Precipitated complexes were washed three times with icecold lysis buffer and analyzed by western blotting, following standard protocols. The following antibodies were used in western blotting; 2 µg ml −1 FCRL5 clone F25 (from Satoshi Nagata), 0.07 µg ml − 
Antibody-dextran conjugates
Covalently linked antibody-dextran conjugates were made at Fina Biosolutions (Rockville, MD, USA), similarly as described previously (29) . Fab fragments of the following antibodies were conjugated to dextran: goat anti-IgM (Jackson ImmunoResearch); anti-FCRL5 clone F99 (from Satoshi Nagata); anti-CD21 clone HB5 (purified using hybridoma obtained from ATCC); non-specific mouse IgG (Jackson ImmunoResearch); non-specific mouse IgG2b (Biolegend). Fab fragments of the FCRL5, CD21 and mouse IgG2b mAbs were made using a kit from Pierce, following the manufacturer's instructions. In all conjugated samples, 1 mg dextran and a total of 1 mg Fab fragment were used.
The following dextran conjugates were made side-by-side; 0. Conjugates were purified by gel filtration, pooling the high-molecular-weight void volume fractions. Actual protein concentrations of the conjugated samples were determined by the BCA assay by absorption at 280 nm (dextran does not absorb at this wavelength). The efficiency of antibody conjugation to dextran was monitored by sizeexclusion high-performance liquid chromatography, which showed no free antibody or free dextran, indicating essentially 100% antibody conjugation efficiency in all samples. When stimulating cells, conjugates were used at the same defined protein concentration, determined in preliminary experiments.
Calcium mobilization assay
When using Daudi cells, 10 6 cells per sample were washed in PBS containing 1% FBS, resuspended in 0.5 ml and loaded with 3 µg Fluo-4 and 7.5 µg Fura-Red (Life Technologies, Grand Island, NY, USA) for 30 min at 30°C. Cells were then washed twice, resuspended in 1 ml PBS with 1% FBS. Samples were warmed at 37°C for 5 min, followed by data acquisition using a flow cytometer (FacsCalibur). To establish a baseline, cells were first acquired for 30 s, at which point dextran conjugates were added and the signal was recorded for ~8 min. Data were analyzed using FlowJo (Treestar, Ashland, OR, USA).
Mononuclear cells isolated from tonsils using standard protocols were frozen by resuspending the cells in ice-cold FBS, then adding dropwise equal parts of ice-cold optimized freezing medium [RPMI with 20% dimethyl sulfoxide (DMSO), 60 mM HEPES and 4 mM sodium pyruvate]. Prior to using in experiments, frozen tonsil cells were thawed, washed in culture medium and rested for 30 min at 37°C. Viability of thawed FCRL5 + tonsil B cells was >90%. 10 7 tonsil cells per sample were incubated with 2 µM Indo-1/AM (Thermo Fisher Scientific, Waltham, MA, USA) and 0.045% Pluronic F-127 in cell culture medium for 30 min at 37°C. The cells were stained with a CD19 antibody to mark B cells. Washed cells were then resuspended in Dulbecco's PBS with 2% FBS and warmed to 37°C for at least 20 min prior to stimulation. Cells were stimulated with dextran conjugates and the calcium response was recorded for 9 min. The relative concentration of intracellular free Ca 2+ in specific live cell populations was calculated using FlowJo as the fluorescence ratio of Indo-1 bound (violet)/Indo-1 unbound (blue). Baselines of samples were aligned prior to comparison.
Results
FCRL5 constitutively associates with CD21, while CD19 is recruited upon FCRL5 engagement
We hypothesized that FCRL5 might form a membrane complex with CD21, allowing co-engagement of the two receptors by their corresponding ligands IgG and C3d, which can be contained in physiological immune complexes. The interaction of FCRL5 and CD21 was first assessed using Daudi B cells stably expressing FCRL5 (Daudi-FCRL5 cells) (Supplementary Figure 1 shows surface FCRL5, CD21, IgM and CD32 expression). The anti-FCRL5 mAbs used for immunoprecipitation and western blotting are extensively characterized; both bind the N-terminal FCRL5 domain with high affinity and specificity (22, 25, 30) . Capitalizing The CD21-FCRL5 receptor complex activates B cells 571 on our well-characterized anti-FCRL5 and anti-CD21 mAbs, we based our experimental approach on the reported discovery of the CD21-CD19 association, which could only be observed in the presence of digitonin as detergent (3) . We also assessed whether the interaction of FCRL5 and CD21 can be modulated by BCR or FCRL5 engagement. Cell lysates prepared in buffers containing either digitonin or triton X-100 as detergent were immunoprecipitated with CD21 or isotype control antibodies, then analyzed by western blotting. We found that FCRL5 was present in the complex pulled down with CD21 antibody in the presence of either detergent ( Fig. 1A and B) . Note that membrane proteins, in particular FCRL5, could be extracted from cells more efficiently using triton X-100 compared to digitonin, as indicated by the presence of consistently stronger bands in western blotting. The FCRL5-CD21 complex could be detected in extracts of unstimulated cells, while pre-treatment of cells with FCRL5 and/or IgM antibodies did not alter the amount of FCRL5 present in the complex. The CD21 antibody also pulled down CD19 in the presence of digitonin (Fig. 1A) , but not when triton was used as detergent (Fig. 1B) , in agreement with published studies indicating the CD21-CD19 complex is disrupted in the presence of strong detergents but is preserved when digitonin is used (3) . Notably, the FCRL5-CD21 complex readily formed in the absence of CD19 (Fig. 1B) , indicating that CD19 is dispensable for the interaction. Resistance of the FCRL5-CD21 complex to triton, which disrupted the CD19-CD21 complex, suggested considerable stability.
We investigated whether CD19, a key CD21-interacting protein, can also associate with FCRL5. When extracting membrane proteins using digitonin, CD21 remains in complex with CD19, therefore we used triton as detergent to assess whether 
The CD21-FCRL5 receptor complex activates B cells
CD19 interacts with FCRL5 in the absence of CD21. Daudi-FCRL5 lysates made using triton were immunoprecipitated with CD19 antibody, followed by western blot analysis. We found CD19 to co-precipitate with FCRL5 in the absence of CD21, but only if cells had been stimulated through FCRL5, either alone or in combination with the BCR (Fig. 2A) . In contrast, stimulation through the BCR alone did not promote the association of FCRL5 and CD19. Identical results were obtained using Rec-1 cells expressing endogenous FCRL5 (Fig. 2B; Supplementary  Figure 1) . To establish the kinetics of the formation of the FCRL5-CD19 complex, Daudi-FCRL5 cells were stimulated for up to 8 min through FCRL5 and the BCR, or FCRL5 alone. We found the FCRL5-CD19 complex to be already maximally formed upon 1 min of FCRL5 stimulation and it was stable for at least 8 min (Fig. 2C) . Co-engagement of the BCR did not influence the formation or stability of the FCRL5-CD19 complex.
Cell surface protein mobility, mediated in part by the actin cytoskeleton, plays crucial roles in B-cell signaling (31) . In order to determine whether the actin cytoskeleton plays a role in the interaction of FCRL5 and CD19, Daudi-FCRL5 cells were pre-treated with cytochalasin D, blocking actin polymerization. We found that cytochalasin D did not affect formation of the FCRL5-CD19 complex, suggesting the actin cytoskeleton is not involved in the interaction (Fig. 2D) . Next, we considered the role of the four tyrosine-containing signaling motifs contained in the FCRL5 cytoplasmic tail in mediating the formation of CD19-FCRL5 complexes through recruited signaling components. The four tyrosines in these signaling motifs were changed to phenylalanine to generate two stable Daudi cell lines with mutated FCRL5. In FCRL5-Y899F/Y912F (M1), the two mutated tyrosines were in non-canonical ITAMs, whereas in FCRL5-Y924F/Y954F (M2), the two mutated tyrosines were in canonical ITIMs. Daudi cells expressing wild-type and mutant FCRL5 had comparable levels of surface FCRL5, CD21, IgM and CD32 (Supplementary Figure 1) . Daudi cells stably expressing these FCRL5 variants were assessed for the formation of the CD19-FCRL5 complex. Cells were stimulated for 2 min through FCRL5, and the formation of the FCRL5-CD19 complex was assessed. We found mutation of the FCRL5 ITAMs or ITIMs had no effect on the interaction with CD19 (Fig. 2E) . In summary, neither the actin cytoskeleton nor the known signaling motifs contained within the cytoplasmic tail of FCRL5 are required to mediate the association of CD19 and FCRL5.
FCRL5 interacts with activating signaling molecules and promotes calcium influx when co-engaged with CD21 on cell lines
Recruitment of CD19 to FCRL5 suggested a potential role for CD19 in mediating signaling events downstream of FCRL5. Therefore, we tested whether FCRL5 engagement modulated CD19 phosphorylation or BCR-induced PI3K recruitment to CD19, two key signaling events. BCR stimulation led to CD19 phosphorylation and PI3K recruitment, as expected (Fig. 3A) . FCRL5 stimulation alone did not induce these signaling events, nor modulate them in co-engagement with the BCR. Next, we assessed whether activating signaling components are recruited to FCRL5 upon its engagement. We chose to monitor PLCγ2 and BTK, two signaling molecules regulating calcium mobilization downstream of CD19. We found that both PLCγ2 and BTK were temporarily recruited to FCRL5 upon its engagement (Fig. 3B) . Moreover, a fraction of PLCγ2 that associated with FCRL5 was phosphorylated on Y759, indicating the presence of protein with lipase activity.
While CD21 strongly promotes BCR-induced calcium signaling (11), FCRL5 was reported to inhibit it (23). We used dextran particles covalently linked with defined amounts of Fab fragments of the specific antibodies or isotype control antibodies to engage these receptors under controlled conditions. We first verified whether in our experimental system FCRL5 inhibited BCR-induced calcium signaling. High-density anti-IgM linked to dextran elicited robust calcium influx in Daudi-FCRL5 cells, and the response was diminished by FCRL5 co-engagement (Fig. 3C, left panel) . Inhibition of BCR signaling by FCRL5 required intact ITIMs, while the ITAM-like motifs were dispensable (Fig. 3C, middle and right panel, respectively) , as reported (23) . Next, we assessed the functional consequences of triple engagement of FCRL5, CD21 and the BCR. Co-stimulation through CD21 is best achieved in the context of suboptimal BCR stimulation (2, 8) . Therefore, in these experiments, a new set of dextran conjugates with suboptimal anti-IgM density was used, together with anti-CD21, anti-FCRL5 and/or isotype control antibodies. Dextran linked to a suboptimal amount of anti-IgM did not elicit a calcium influx (Fig. 3D) , similarly to published studies (7, 9) . When CD21 was co-engaged with the BCR, sustained calcium influx was detected in wild-type and mutant Daudi-FCRL5 cells, in accordance with CD21 promoting BCR signaling. Triple engagement of FCRL5, CD21 and BCR resulted in strikingly higher calcium influx than that produced by CD21 and BCR double engagement. Notably, wildtype, ITIMs mutant, and ITAM mutant FCRL5 equally promoted the calcium influx, indicating the mutated signaling motifs are dispensable for the activity.
A subset of tonsil B cells co-expresses FCRL5 and CD21 and robustly responds to triple engagement of the BCR, CD21 and FCRL5
FCRL5
+ B cells in the peripheral blood of healthy donors are rare and the majority of FCRL5 + B cells lack CD21 (25) . Therefore, we investigated whether B cells that co-express FCRL5 and CD21 existed in lymphoid tissues. We found that among B cells obtained from human tonsils, on average 24% expressed FCRL5. Moreover, the majority of FCRL5 + tonsil B cells co-expressed CD21; 20.36 ± 1.6% (mean and SD) of tonsil B cells were FCRL5 + CD21 + , while 3.4 ± 0.23% were FCRL5 + CD21 − (Fig. 4A) . Therefore, we used tonsil B cells to assess the functional impact of BCR, FCRL5 and CD21 co-engagement on primary B cells. Tonsil B cells did not respond to suboptimal IgM stimulation, while CD21 costimulation resulted in a calcium influx, similarly to our cell line model. Additional engagement of FCRL5 produced a consistently robust calcium response that was stronger than BCR/CD21 double-stimulation (Fig. 4B) . We note this experimental approach likely underestimated the impact of FCRL5 engagement, because CD21 + cells that lack FCRL5 contribute to the signal obtained upon double-stimulation, but not triple stimulation. We conclude that in tonsil B cells FCRL5 promotes BCR-induced calcium signaling when CD21 is co-engaged. C) were pre-loaded with calcium indicator dyes. Cells were then stimulated through the BCR, CD21 and/or FCRL5, as indicated, using 6 µg ml −1 total protein on dextran conjugates, made using a low (suboptimal) amount of anti-BCR. Representative calcium flux plots of three independent experiments are shown.
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Discussion
We report formation of a functional receptor complex by CD21 and FCRL5. Strikingly, the enhancement of BCR signaling by CD21 and FCRL5 co-engagement surpassed that afforded by CD21 alone. We propose that immune complexes containing both IgG and C3 fragments can engage the pre-formed FCRL5-CD21 complex, resulting in superior B-cell activation.
We found FCRL5 to constitutively associate with CD21, and the interaction was not modulated by BCR or FCRL5 engagement (Fig. 1) . The FCRL5-CD21 complex was resistant to triton, a detergent known to disrupt the CD19-CD21 complex, indicating that CD19 plays no role in its formation (Fig. 1B) . Furthermore, cross-linking of FCRL5 resulted in rapid recruitment of CD19 to FCRL5 (Fig. 2C) . The interaction of CD19 and FCRL5 could be detected in the presence of triton as detergent, suggesting it is not mediated by CD21, which was not present in the complex under these conditions (Fig. 2A) . The mouse mAbs used for IP are expected to bind FCRL5 with very low affinity (75 µM) (22) , and any residual binding would be identified by the signal obtained using the isotype control sample. The actin cytoskeleton plays a key role regulating B-cell signaling, such as the formation of BCR microclusters leading to a functional immunological synapse (15, 32, 33) . We found that inhibition of actin polymerization did not interfere with the formation of the FCRL5-CD19 complex (Fig. 2D) . Furthermore, CD19 similarly associated with FCRL5 with tyrosines mutated in two ITAMs or two ITIMs, excluding a role of SH2 domain-containing interacting proteins bridging CD19 and FCRL5 (Fig. 2E) . Therefore, the mechanism of CD19 integration into the FCRL5-CD21 complex remains unclear. Nevertheless, CD19-FCRL5 complexes apparently formed in the absence of CD21 ( Fig. 2A) , while CD21-FCRL5 complexes were formed in the absence of CD19 (Fig. 1B) , suggesting FCRL5 can interact with each molecule independently. One possible interpretation of our findings is that FCRL5 and CD21 closely associate on resting cells, while CD21 also maintains interaction with CD19. Upon FCRL5 engagement, a rapid rearrangement of these three molecules leads to close spatial interaction of FCRL5 and CD19.
The association of CD19 with FCRL5 raises the possibility that together they form a unique signaling module. The cytoplasmic tail of CD19 contains nine tyrosine signaling motifs that upon phosphorylation create docking sites for many signaling proteins, including Vav, PI3K, Lyn, Fyn, PLCγ2, Grb-2 and BTK (13, (34) (35) (36) . The two ITIMs of FCRL5 were demonstrated to mediate recruitment of SHP-1 following cocross-linking with the BCR; however, no functional role for the two ITAM-like motifs was proposed (23) . To test one possible The CD21-FCRL5 receptor complex activates B cells 575 mode of cross-talk, we assessed whether FCRL5 engagement resulted in CD19 phosphorylation, as rapid tyrosine phosphorylation of CD19 is the main initiator of downstream signaling pathways. FCRL5 cross-linking for 2 min did not affect CD19 phosphorylation (Fig. 3A) . Nevertheless, temporary phosphorylation events occurring at other time points cannot be excluded. We found that upon FCRL5 engagement PLCγ2 and BTK were temporarily recruited to FCRL5 (Fig. 3B) . BTK is known to phosphorylate Tyr753 and Tyr759 of PLCγ2, resulting in activation of its lipase activity (37, 38) . In turn, activated PLCγ2 promotes the formation of inositol-1,4,5-trisphosphate leading to calcium release from intracellular stores (39) . PLCγ2 recruited to FCRL5 was found phosphorylated on Tyr759, consistent with active PLCγ2, potentially contributing to downstream calcium mobilization (Fig. 3B) . Therefore, we assessed whether co-engagement of FCRL5 and CD21 modulates BCR-induced calcium signaling. We verified our experimental system of Daudi cells stably expressing FCRL5 to be a relevant model, because CD21 strongly promoted suboptimal BCR-induced calcium signaling (Fig. 3D) , while FCRL5 inhibited optimal BCR-induced calcium signaling (Fig. 3C) , as reported. Under conditions of suboptimal BCR stimulation, CD21 cross-linking produced robust calcium mobilization in Daudi-FCRL5 cells, which was strikingly enhanced by FCRL5 co-engagement (Fig. 3D) . We did not use human IgG to engage FCRL5 in the present proof-of-concept study, as human IgG also binds CD32 which is expressed at high levels on Daudi (Supplementary Figure 1) , preventing determination of the functional role of FCRL5. Furthermore, BCR co-stimulation is essential and requires anti-immunoglobulin antibodies that cannot be substituted with a model antigen in a human system. Importantly, the findings in cell lines were recapitulated in tonsil B cells that co-express endogenous FCRL5 and CD21. In tonsil B cells, triple engagement of FCRL5, CD21 and BCR resulted in higher calcium influx than that produced by CD21 and BCR double engagement (Fig. 4B) . We conclude that FCRL5 promotes BCR calcium signaling when co-engaged with CD21. Demonstration of a functional response to CD21-FCRL5 co-stimulation can be considered an independent support for the observed physical association, which may be direct or indirect. The robust calcium signal produced by FCRL5, CD21 and BCR triple stimulation could be predicted to promote B-cell proliferation and antibody secretion, similarly as observed upon CD21 costimulation (2, 8) . Alternatively, FCRL5-derived signals may lead to a subsequent B-cell response that qualitatively differs from that observed upon CD21 co-stimulation. We propose the following model for cells co-expressing FCRL5 and CD21. In resting B cells, FCRL5 and CD21 form a pre-assembled receptor complex. Engagement of FCRL5 leads to rapid recruitment of a number of activating signaling molecules, including CD19, BTK and active PLCγ2. At this junction, whether CD21 is co-ligated will lead to opposing functional outcomes. In the absence of CD21 engagement, FCRL5 acts as a negative regulator of the BCR by recruiting SHP-1 and inhibiting B-cell activation. If CD21 is co-engaged, such as by IgG immune complexes with deposited C3 fragments, FCRL5 promotes calcium signaling, leading to B-cell activation. Binary function is an emerging theme for proteins in the FCRL family. Human FCRL3, when co-ligated with the BCR, inhibits protein tyrosine phosphorylation and calcium mobilization. In contrast, FCRL3 promotes TLR9-mediated B-cell proliferation, activation and survival, yet represses plasma cell differentiation and antibody production. Similarly, human FCRL4 was found to block BCR-induced signaling, yet promote TLR9 signaling, despite containing only ITIM signaling motifs. Mouse FCRL5 was also demonstrated to have a dual effect on BCR signaling, in a B-cell subset-dependent manner (40) .
The relationship of CD21 and FCRL5 expression on B cells is intriguing and potentially instructive ( Table 1) . We and others reported a subset of circulating atypical memory B cells, which are rare in healthy blood but accumulate under chronic antigen stimulation, to express FCRL5 but lack CD21 (25, 41) , suggesting that these cells are prone to negative regulation by FCRL5. Indeed, FCRL5 + CD21 − tissue-like memory B cells are functionally anergic to BCR stimulation. In contrast, we found ~20% of B cells in tonsil tissue to co-express CD21 and FCRL5 and robustly respond to FCRL5/CD21/BCR triple engagement (Fig. 4) 
CD21
+ B cells in healthy tonsil tissue, but not in peripheral blood. We propose that in lymphoid tissues, B cells co-expressing FCRL5 and CD21 have the unique ability to robustly respond to antigen in complex with IgG and C3 fragments. An antigen-IgG-C3 fragment immune complex might be considered a mark of an unresolved or chronic infection, as the antigen is not cleared despite a class-switched IgG response and productive complement activation. In such a scenario, a unique FCRL5 + CD21 + B-cell subset might be engaged to overcome the deadlock. 
